{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:19:59Z","timestamp":1773886799305,"version":"3.50.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"publisher","award":["121\/24.06.2020"],"award-info":[{"award-number":["121\/24.06.2020"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Present study describes a high-performance liquid chromatography method for the determination of the potent kinetic stabilizer\u2014Tafamidis in human plasma. It was approved for medical use in European Union in 2011. Ultra violet (UV) detection mode and isocratic elution of the mobile phase were set and made the analytical procedure fast and widely applicable. Chromatographic determination was performed on a Purospher\u00ae RP-18 column. The mobile phase consisted of 0.1% trifluoroacetic acid in water and acetonitrile in the ratio 42:58\u00a0v\/v and the flow rate was 1.0\u00a0ml\/min. All analyses were carried at a room temperature and the detector was set at 280\u00a0nm. Calibration curve over a range of 1.00\u201310.00\u00a0\u03bcM was constructed for the purposes of linearity method validation. The specificity and effectiveness of the developed method made it suitable for observation of patients\u2019 plasma Tafamidis concentration with time and drug therapy monitoring.<\/jats:p>","DOI":"10.1093\/chromsci\/bmab132","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T20:16:31Z","timestamp":1636143391000},"page":"840-847","source":"Crossref","is-referenced-by-count":12,"title":["Determination of Tafamidis Plasma Concentrations in Amyloidosis Patients with Glu89Gln Mutation by HPLC-UV Detection"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5106-1036","authenticated-orcid":false,"given":"Miglena","family":"Smerikarova","sequence":"first","affiliation":[{"name":"Department of Chemistry , Faculty of Pharmacy, Medical University, Dunav Str. no. 2, Sofia 1000, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislav","family":"Bozhanov","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Faculty of Pharmacy, Medical University, Dunav Str. no. 2, Sofia 1000, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vania","family":"Maslarska","sequence":"additional","affiliation":[{"name":"Department of Chemistry , Faculty of Pharmacy, Medical University, Dunav Str. no. 2, Sofia 1000, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivailo","family":"Tournev","sequence":"additional","affiliation":[{"name":"Clinic of Nervous Diseases , UMBAL Aleksandrovska, Department of Neurology, Medical University, Sv. Georgi Sofiiski Str. no. 1, Sofia 1431, Bulgaria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,12,11]]},"reference":[{"key":"2022110707381222100_ref1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? An European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Current Opinion in Neurology"},{"key":"2022110707381222100_ref2","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0006-291X(85)91956-4","article-title":"Localization of the human prealbumin gene to chromosome 18","volume":"129","author":"Wallace","year":"1985","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"2022110707381222100_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20122982","article-title":"Diagnostic and treatment approaches involving transthyretin in amyloidogenic diseases","volume":"20","author":"Park","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"2022110707381222100_ref4","doi-asserted-by":"crossref","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"},{"key":"2022110707381222100_ref5","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.2174\/138161208786404155","article-title":"Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses","volume":"14","author":"Sekijima","year":"2008","journal-title":"Current Pharmaceutical Design"},{"key":"2022110707381222100_ref6","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120308998998","article-title":"Tabulation of human transthyretin (TTR) variants, 2003","volume":"10","author":"Connors","year":"2003","journal-title":"Amyloid"},{"key":"2022110707381222100_ref7","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","article-title":"First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy","volume":"29","author":"Adams","year":"2016","journal-title":"Current Opinion in Neurology"},{"key":"2022110707381222100_ref8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1756285612470192","article-title":"Recent advances in the treatment of familial amyloid polyneuropathy","volume":"6","author":"Adams","year":"2013","journal-title":"Therapeutic Advances in Neurological Disorders"},{"key":"2022110707381222100_ref9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/DNND.S24624","article-title":"Evaluation of tafamidis as first-line therapeutic agent for transthyretin familial amyloidotic polyneuropathy","volume":"2","author":"Joel","year":"2012","journal-title":"Degenerative Neurological and Neuromuscular Disease"},{"key":"2022110707381222100_ref10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-014-0260-2","article-title":"Tafamidis: A review of its use in familial amyloid polyneuropathy","volume":"74","author":"Scott","year":"2014","journal-title":"Drugs"},{"key":"2022110707381222100_ref11","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1121005109","article-title":"Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade","volume":"109","author":"Bulawa","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"2022110707381222100_ref12","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ene.12225","article-title":"Effect on disability and safety of tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy","volume":"20","author":"Lozeron","year":"2013","journal-title":"European Journal of Neurology"},{"key":"2022110707381222100_ref13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/13506129.2016.1207163","article-title":"Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy","volume":"23","author":"Waddington Cruz","year":"2016","journal-title":"Amyloid"},{"key":"2022110707381222100_ref14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/ene.13510","article-title":"Tafamidis delays neurological progression comparably across Val30Met and non-Val30Met genotypes in transthyretin familial amyloid polyneuropathy","volume":"25","author":"Gundapaneni","year":"2018","journal-title":"European Journal of Neurology"},{"key":"2022110707381222100_ref15","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-020-00180-w","article-title":"Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: Clinical trial results up to 8.5 years","volume":"9","author":"Merlini","year":"2020","journal-title":"Neurology and Therapy"},{"key":"2022110707381222100_ref16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40267-016-0368-4","article-title":"Tafamidis in transthyretin amyloidosis: A guide to its use in delaying peripheral neurological impairment in patients with stage 1 polyneuropathy","volume":"33","author":"McKeage","year":"2017","journal-title":"Drugs and Therapy Perspectives"},{"key":"2022110707381222100_ref17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40120-018-0097-9","article-title":"Positive effectiveness of tafamidis in delaying disease progression in transthyretin familial amyloid polyneuropathy up to 2 years: An analysis from the transthyretin amyloidosis outcomes survey (THAOS)","volume":"7","author":"Mundayat","year":"2018","journal-title":"Neurology and Therapy"},{"key":"2022110707381222100_ref18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"2022110707381222100_ref19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40120-018-0096-x","article-title":"Understanding the disease course and therapeutic benefit of tafamidis across real-world studies of hereditary transthyretin amyloidosis with polyneuropathy: A proof of concept for integrative data analytic approaches","volume":"7","author":"Serrano","year":"2018","journal-title":"Neurology and Therapy"},{"key":"2022110707381222100_ref20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40119-020-00179-2","article-title":"Extrapolation of survival benefits in patients with transthyretin amyloid cardiomyopathy receiving tafamidis: Analysis of the tafamidis in transthyretin cardiomyopathy clinical trial","volume":"9","author":"Li","year":"2020","journal-title":"Cardiology and Therapy"},{"key":"2022110707381222100_ref21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/13506129.2015.1063485","article-title":"Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)","volume":"22","author":"Cho","year":"2015","journal-title":"Amyloid"},{"key":"2022110707381222100_ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cjca.2019.11.036","article-title":"CCS\/CHFS heart failure guidelines: Clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O\u2019Meara","year":"2020","journal-title":"Canadian Journal of Cardiology"},{"key":"2022110707381222100_ref23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hrtlng.2020.02.009","article-title":"Efficacy of tafamidis in transthyretin amyloid cardiomyopathy in the ATTR-ACT trial","volume":"49","author":"Berk","year":"2020","journal-title":"Heart & Lung"},{"key":"2022110707381222100_ref24","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1021\/bi500171j","article-title":"Quantification of transthyretin kinetic stability in human plasma using subunit exchange","volume":"53","author":"Rappley","year":"2014","journal-title":"Biochemistry"},{"key":"2022110707381222100_ref25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 \u00d7 20-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clinical Pharmacology in Drug Development"},{"key":"2022110707381222100_ref26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/jci.insight.126526","article-title":"Predictive model of response to tafamidis in hereditary ATTR polyneuropathy","volume":"4","author":"Monteiro","year":"2019","journal-title":"JCI Insight"},{"key":"2022110707381222100_ref27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/13506129.2018.1479249","article-title":"Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients","volume":"25","author":"Monteiro","year":"2018","journal-title":"Amyloid"},{"key":"2022110707381222100_ref28","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/00498254.2017.1366575","article-title":"Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats","volume":"48","author":"Lee","year":"2018","journal-title":"Xenobiotica"},{"key":"2022110707381222100_ref29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpba.2017.01.020","article-title":"Development and validation of a liquid chromatography\u2013tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats","volume":"137","author":"Hyun","year":"2017","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2022110707381222100_ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0174777","article-title":"Development and validation of reversed phase HPLC gradient method for the estimation of efavirenz in plasma","volume":"12","author":"Gupta","year":"2017","journal-title":"PLoS One"},{"key":"2022110707381222100_ref31","first-page":"1","article-title":"Determination of 2,4-dichlorophenoxyacetic acid (2,4-d) in rat serum for pharmacokinetic studies with a simple HPLC method","volume":"13","author":"Chen","year":"2018","journal-title":"PLoS One"},{"key":"2022110707381222100_ref32","volume-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Bioanalytical Method Validation: Text and Methodology M10, Current Step 2b version","year":"2019"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/60\/9\/840\/46822231\/bmab132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/60\/9\/840\/46822231\/bmab132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T07:39:22Z","timestamp":1667806762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/60\/9\/840\/6459931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,11]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,12,11]]},"published-print":{"date-parts":[[2022,11,5]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmab132","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10]]},"published":{"date-parts":[[2021,12,11]]}}}